Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

NCT03308201 is registered in ClinicalTrials.gov with Tianjin Hemay Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT03308201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03308201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer
Lead sponsor
Tianjin Hemay Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
October 16, 2017
Completion date
March 1, 2023
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer